EP1315499A4 - Compositions and methods for the treatment of anorectal disorders - Google Patents

Compositions and methods for the treatment of anorectal disorders

Info

Publication number
EP1315499A4
EP1315499A4 EP01957348A EP01957348A EP1315499A4 EP 1315499 A4 EP1315499 A4 EP 1315499A4 EP 01957348 A EP01957348 A EP 01957348A EP 01957348 A EP01957348 A EP 01957348A EP 1315499 A4 EP1315499 A4 EP 1315499A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
anorectal disorders
anorectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01957348A
Other languages
German (de)
French (fr)
Other versions
EP1315499A1 (en
Inventor
Thomas P Parks
Vivien Mak
Jung-Chung Lee
Charles Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strakan International Ltd Great Britain
Original Assignee
Strakan International Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strakan International Ltd Great Britain filed Critical Strakan International Ltd Great Britain
Publication of EP1315499A1 publication Critical patent/EP1315499A1/en
Publication of EP1315499A4 publication Critical patent/EP1315499A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
EP01957348A 2000-07-31 2001-07-30 Compositions and methods for the treatment of anorectal disorders Withdrawn EP1315499A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22226700P 2000-07-31 2000-07-31
US222267P 2000-07-31
PCT/US2001/023971 WO2002009714A1 (en) 2000-07-31 2001-07-30 Compositions and methods for the treatment of anorectal disorders

Publications (2)

Publication Number Publication Date
EP1315499A1 EP1315499A1 (en) 2003-06-04
EP1315499A4 true EP1315499A4 (en) 2007-09-05

Family

ID=22831555

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01957348A Withdrawn EP1315499A4 (en) 2000-07-31 2001-07-30 Compositions and methods for the treatment of anorectal disorders

Country Status (8)

Country Link
EP (1) EP1315499A4 (en)
JP (1) JP2004516244A (en)
KR (3) KR100863758B1 (en)
AU (1) AU2001279104A1 (en)
CA (1) CA2417848A1 (en)
IL (1) IL154202A0 (en)
MX (1) MXPA03000931A (en)
WO (1) WO2002009714A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
KR101067443B1 (en) 2009-06-23 2011-09-27 여오영 Local injection composition comprising hydroxychloroquine for treatment of hemorrhoids
CN102145004B (en) * 2010-02-09 2012-03-21 鲁南制药集团股份有限公司 Application of pentoxifylline to preparing medicaments for preventing or treating functional constipation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043354A2 (en) * 1998-02-27 1999-09-02 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595753A (en) 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043354A2 (en) * 1998-02-27 1999-09-02 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0209714A1 *

Also Published As

Publication number Publication date
MXPA03000931A (en) 2004-08-12
CA2417848A1 (en) 2002-02-07
AU2001279104A1 (en) 2002-02-13
KR20080068145A (en) 2008-07-22
KR20100017750A (en) 2010-02-16
KR20030024826A (en) 2003-03-26
WO2002009714A9 (en) 2003-03-06
WO2002009714A1 (en) 2002-02-07
IL154202A0 (en) 2003-07-31
KR100863758B1 (en) 2008-10-16
EP1315499A1 (en) 2003-06-04
JP2004516244A (en) 2004-06-03

Similar Documents

Publication Publication Date Title
PL348817A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
GB0007193D0 (en) Treatment of movrmrnt disorders
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1578385A4 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
PL351134A1 (en) Compositions for treatment of disorders of the oesophagus
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
EP1356278A4 (en) Methods and compositions for the identification and treatment of neurodegenerative disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
EP1335736A4 (en) Compositions and methods for diagnosis and treatment of cardiovascular disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU9527001A (en) Treatment of T cell disorders
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
IL155874A0 (en) Treatment of anxiety disorders
EP1315499A4 (en) Compositions and methods for the treatment of anorectal disorders
AU6137801A (en) Method and composition for the treatment of angiogenesis
EP1440080A4 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders
EP1440165A4 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
EP1440167A4 (en) Methods and compositions for the diagnosis and treatment of hematological disorders using 16319
EP1440166A4 (en) Methods and compositions for the diagnosis and treatment of hematological disorders using 2777

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030214

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEE, CHARLES

Inventor name: LEE, JUNG-CHUNG

Inventor name: MAK, VIVIEN

Inventor name: PARKS, THOMAS, P.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLEGY PHARMACEUTICALS, INC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLEGY PHARMACEUTICALS, INC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: STRAKAN INTERNATIONAL LIMITED

111Z Information provided on other rights and legal means of execution

Free format text: ATBECHCYDEDKESFIFRGBGRIEITLUMCNLPTSETR

Effective date: 20070517

A4 Supplementary search report drawn up and despatched

Effective date: 20070808

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080114